SCM
AVBP icon

Sterling Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Sterling Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62K Sell
133
-76
-36% -$2.24K ﹤0.01% 2660
2026
Q1 		$4.82K Buy
209
+22
+12% +$497 ﹤0.01% 2750
2025
Q4 		$3.76K Buy
187
+127
+212% +$2.64K ﹤0.01% 2966
2025
Q3 		$1.11K Buy
60
+4
+7% +$79 ﹤0.01% 3065
2025
Q2 		$1.22K Sell
56
-153
-73% -$3.18K ﹤0.01% 3030
2025
Q1 		$3.86K Sell
209
-164
-44% -$4.01K ﹤0.01% 2288
2024
Q4 		$9.94K Buy
373
+314
+532% +$9.02K ﹤0.01% 2165
2024
Q3 		$1.39K Buy
+59
New +$1.34K ﹤0.01% 2373

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's AVBP Position: Q2 2026 in Review

Sterling Capital Management reduced its ArriVent BioPharma (AVBP) stake by 36% in Q2 2026, selling an estimated $2.24K and leaving 133 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

Sterling Capital Management first reported a position in AVBP in Q3 2024 and has held it in 8 quarters since. The position peaked at $9.94K in Q4 2024. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Sterling Capital Management held 133 shares of ArriVent BioPharma worth $4.62K as of Q2 2026.
  • Sterling Capital Management sold 76 ArriVent BioPharma shares in Q2 2026, an estimated $2.24K.
  • ArriVent BioPharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2660 holding.
  • Sterling Capital Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's ArriVent BioPharma position peaked at $9.94K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.